NeanderThin: Eat Like a Caveman to Achieve a Lean, Strong, Healthy Body (Hardcover) by Ray Audette, with Troy Gilchrist, was one of the early paleo diet authors. His home page NeanderThin [now restored from archive.org] has a diet based on the ideas of paleolithic nutrition. The diet can be followed as a low-carb, moderate or high carb diet, depending upon whether and how much fruit is used. You can read up through page 19 of the book at Google Books. The original press release from 1999. [The webmaster has an extra copy with the author's signature for sale. It has the original lime-purple cover. Pristine new condition. $60 (shipping included). Paypal only. Use e-mail link at page bottom.]
With a very simple shift we not only remove the foods that are at odds with our health (grains, legumes, and dairy) but we also increase our intake of vitamins, minerals, and antioxidants. Here is a great paper from Professor Loren Cordain exploring how to build a modern Paleo diet: The nutritional characteristics of a contemporary diet based upon Paleolithic food groups. This paper also offers significant insight as to the amounts and ratios of protein, carbohydrate and fat in the ancestral diet.
CrossFit, Inc. does not dispute that its methodology has the potential to cause rhabdomyolysis. The company states that exertional rhabdomyolysis can be found in a wide variety of sports and training populations and argues that its critics have conflated CrossFit's high awareness of rhabdomyolysis with high risk. One CrossFit spokesman stated that "ESPN's report on the 53 deaths in US triathlons from 2007 to 2013 should have put the issue to rest."
The WHO trial (so named because the international team of principal investigators contained World Health Organization members) tested the potential of clofibrate, a “pre-statin” cholesterol-lowering agent, to reduce heart attack morbidity and mortality. The investigators ultimately concluded that clofibrate "cannot be recommended as a lipid-lowering drug for community-wide primary prevention of ischaemic heart disease.” Nevertheless, clofibrate remained in use until 2002, when it was pulled for increasing cancer rates. In their review of studies such as the WHO trial, Uffe Ravnskov and David Diamond observe, “Despite the largely disappointing findings from 50 years of cholesterol lower[ing] trials, the indictment and conviction of cholesterol as the causal agent in CVD [cardiovascular disease] has stood the test of time. … [Yet] the grand effort to reduce cholesterol as a strategy to improve health has failed.”